StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Silence Therapeutics (SLN)

Wed, 17 Jun 2026 06:49:17 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $75.00 price target on Silence Therapeutics (NASDAQ: SLN).

The analyst commented: "Divesiran, a first-in-class GalNAc-conjugated small interfering RNA (siRNA) targeting TMPRSS6, is designed to increase endogenous hepcidin, restrict iron availability for erythropoiesis, and reduce excessive red blood cell production in patients with polycythemia vera (PV). The update presented at the European Hematology Association (EHA 2026) on June 11, focused on the completed Phase 1 portion of the Phase 1/2 SANRECO trial evaluating divesiran, and added important durability, symptom, and iron-biology detail to the previously reported phlebotomy and hematocrit (HCT) profile, including

Form 8-K Silence Therapeutics For: Jun 16

Tue, 16 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26655059.html

Form 8-K Silence Therapeutics For: Jun 16

Tue, 16 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26655059.html

Form 8-K Silence Therapeutics For: Jun 16

Tue, 16 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260616/26655059.html

Form 8-K Silence Therapeutics For: Jun 11

Thu, 11 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260611/26632654.html

Form 8-K Silence Therapeutics For: Jun 11

Thu, 11 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260611/26632654.html

Form 8-K Silence Therapeutics For: Jun 11

Thu, 11 Jun 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260611/26632654.html

Silence Therapeutics presents divesiran follow-up data at EHA 2026

Thu, 11 Jun 2026 07:30:38 -0400

Silence Therapeutics plc (NASDAQ: SLN) presented follow-up data from its Phase 1 SANRECO study evaluating divesiran for polycythemia vera at the European Hematology Association 2026 Annual Congress. The study enrolled 21 phlebotomy-dependent patients with the rare blood cancer.

The data showed reductions in phlebotomy use persisted after treatment ended. In the six months before treatment, patients required 80 phlebotomies total. During active treatment, only 5 phlebotomies were needed. In the 16-week follow-up period after the final dose, 4 phlebotomies were reported.

Among 14 patients with extended follow-up data, the median time to first phlebotomy was 287 days. Most patients showed improvements in

Silence Therapeutics presents divesiran follow-up data at EHA 2026

Thu, 11 Jun 2026 07:30:38 -0400

Among 14 patients with extended follow-up data, the median time to first phlebotomy was 287 days. Most patients showed improvements in

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Thu, 11 Jun 2026 07:30:00 -0400

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life

Follow-up data show substantial reductions in phlebotomy use persisting after final dose

Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependent patients with polycythemia vera (PV) at the European Hematology Association

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Thu, 11 Jun 2026 07:30:00 -0400

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life

Follow-up data show substantial reductions in phlebotomy use persisting after final dose

Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Thu, 11 Jun 2026 07:30:00 -0400

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life

Follow-up data show substantial reductions in phlebotomy use persisting after final dose

Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Thu, 11 Jun 2026 07:30:00 -0400

New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life

Follow-up data show substantial reductions in phlebotomy use persisting after final dose

Phase 2 SANRECO study evaluating Q6W and Q12W dosing remains on-track for topline results in August 2026

Form EFFECT Silence Therapeutics

Thu, 28 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260528/26560572.html

Form EFFECT Silence Therapeutics

Thu, 28 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260528/26560572.html

Form EFFECT Silence Therapeutics

Thu, 28 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260528/26560572.html

Form 424B5 Silence Therapeutics

Wed, 27 May 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260527/26558794.html

Form 424B5 Silence Therapeutics

Wed, 27 May 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260527/26558794.html

Form 424B5 Silence Therapeutics

Wed, 27 May 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260527/26558794.html

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.

A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.

A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.

A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.

A live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered

Form 8-K Silence Therapeutics For: May 18

Mon, 18 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260518/26514863.html

Form 8-K Silence Therapeutics For: May 18

Mon, 18 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260518/26514863.html